Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKRX NASDAQ:GALT NASDAQ:PHAS NASDAQ:SPRO NASDAQ:TLC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKRXAkorn$0.19$0.09▼$5.46$3.60M0.959.60 million shs1.19 million shsGALTGalectin Therapeutics$2.09-2.8%$1.66$0.73▼$3.90$132.28M0.7436,033 shs206,406 shsPHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shs9.65 million shsSPROSpero Therapeutics$2.94+1.4%$1.89$0.51▼$3.09$164.38M1.332.18 million shs629,853 shsTLCTaiwan Liposome$7.00$7.10$4.07▼$7.70$294.54M0.99133,095 shs12,421 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKRXAkorn0.00%0.00%0.00%0.00%0.00%GALTGalectin Therapeutics-0.23%+1.90%+62.88%+69.29%+4.37%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%0.00%+6,910.00%SPROSpero Therapeutics-0.34%0.00%+16.00%+417.86%+121.37%TLCTaiwan Liposome0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKRXAkornN/AN/AN/AN/AN/AN/AN/AN/AGALTGalectin Therapeutics1.6577 of 5 stars3.50.00.00.02.81.70.0PHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASPROSpero Therapeutics3.8777 of 5 stars3.35.00.04.70.00.00.6TLCTaiwan LiposomeN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKRXAkorn 0.00N/AN/AN/AGALTGalectin Therapeutics 3.00Buy$6.00187.08% UpsidePHASPhaseBio Pharmaceuticals 0.00N/AN/AN/ASPROSpero Therapeutics 2.50Moderate Buy$5.0070.07% UpsideTLCTaiwan Liposome 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest AKRX, SPRO, GALT, TLC, and PHAS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKRXAkorn$682.43M0.00N/A0.19$1.86 per share0.00GALTGalectin TherapeuticsN/AN/AN/AN/A($1.68) per shareN/APHASPhaseBio Pharmaceuticals$818K0.00N/AN/A($1.93) per share0.00SPROSpero Therapeutics$47.98M3.43N/AN/A$0.85 per share3.46TLCTaiwan Liposome$3.63M81.14N/AN/A$0.83 per share8.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKRXAkorn-$226.77M-$0.34N/AN/AN/A-55.64%8.53%1.31%N/AGALTGalectin Therapeutics-$47.05M-$0.72N/AN/AN/AN/AN/A-216.05%8/12/2025 (Estimated)PHASPhaseBio Pharmaceuticals-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/ASPROSpero Therapeutics-$68.57M-$1.28N/AN/AN/A-156.48%-123.50%-58.96%8/4/2025 (Estimated)TLCTaiwan Liposome-$35.02M-$0.88N/AN/AN/A-299.27%-120.45%-55.11%N/ALatest AKRX, SPRO, GALT, TLC, and PHAS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025SPROSpero Therapeutics-$0.35N/AN/AN/AN/AN/A5/15/2025Q1 2025GALTGalectin Therapeutics-$0.20-$0.15+$0.05-$0.15N/AN/A5/13/2025Q1 2025SPROSpero Therapeutics-$0.55-$0.25+$0.30-$0.25$11.00 million$5.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKRXAkornN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/ASPROSpero TherapeuticsN/AN/AN/AN/AN/ATLCTaiwan LiposomeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKRXAkorn0.090.500.32GALTGalectin TherapeuticsN/A0.080.08PHASPhaseBio PharmaceuticalsN/A0.470.47SPROSpero TherapeuticsN/A2.562.56TLCTaiwan Liposome0.673.013.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKRXAkorn64.03%GALTGalectin Therapeutics11.68%PHASPhaseBio Pharmaceuticals49.02%SPROSpero Therapeutics25.60%TLCTaiwan Liposome0.22%Insider OwnershipCompanyInsider OwnershipAKRXAkorn3.90%GALTGalectin Therapeutics50.10%PHASPhaseBio Pharmaceuticals9.90%SPROSpero Therapeutics5.50%TLCTaiwan LiposomeN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKRXAkorn2,227133.15 millionN/AOptionableGALTGalectin Therapeutics963.29 million31.58 millionOptionablePHASPhaseBio Pharmaceuticals6049.86 million44.92 millionNot OptionableSPROSpero Therapeutics15055.91 million52.84 millionOptionableTLCTaiwan Liposome2,02042.08 millionN/ANot OptionableAKRX, SPRO, GALT, TLC, and PHAS HeadlinesRecent News About These CompaniesWhat is the TLC Diet?July 8 at 7:59 AM | news-medical.netNThis TLC star bares it all on stage while another rushes into a new relationshipJuly 8 at 7:59 AM | msn.com‘Virgins’ new episode on TLC tonight, how to watch for freeJuly 8 at 7:59 AM | masslive.comMFans Can't Believe TLC's Dr. Now 'Finally Smiled at Something' in 'Adorable' New VideoJuly 8 at 7:59 AM | msn.comAngelo Dawkins Feared Career-Ending Knee Injury In TLC Match – ‘I’m Afraid Of Heights!’July 6 at 12:08 AM | ewrestlingnews.comEThe True and Tragic Story of TLC’s Lisa ‘Left Eye’ LopesJuly 4, 2025 | yahoo.com‘90 Day Fiancé: Happily Ever After?’ Season 9 Cast Photos: Meet The 8 Couples Returning To TLC SeriesJuly 4, 2025 | msn.comTLC Recovery House celebrating 4th Anniversary and Recovery RallyJuly 4, 2025 | msn.comAdult virgins break taboos and take huge emotional risks in tonight’s must-see TLC episodeJuly 1, 2025 | msn.comTLC’s ‘Virgins’ airs new episode tonight - How to watch for freeJuly 1, 2025 | masslive.comM‘Match Me Abroad’ season 2, episode 2; how to watch TLC realityJune 29, 2025 | mlive.comMTLC ‘Virgins’ Star Rhasha Will Have You Blushing With Her Unique Definition of BDSM (Exclusive)June 27, 2025 | usmagazine.comUTLC brings colour, connection to Niche Market Art ShowcaseJune 26, 2025 | citizen.co.zaCPhiladelphia Leadership: Emily Gatto, Director, TLC WellnessJune 26, 2025 | msn.comManchester's TLC Foundation seeks $200,000 to avoid closing Diyeso-Lewis House for homeless childrenJune 26, 2025 | stamfordadvocate.comSHow to watch ‘Match Me Abroad’ Season 2 TLC dating show free or on demandJune 23, 2025 | msn.comTLC’s hit show ‘Match Me Abroad’ returns after 2-year break: How you can watch the new season freeJune 23, 2025 | msn.comStill A Virgin At 34, Reading Man Tries Tantra And Pickup Lines On New TLC ShowJune 12, 2025 | dailyvoice.comD‘1,000-Lb Roomies’ new episode: How to stream new series on TLC for freeJune 12, 2025 | masslive.comMTLC ‘Virgins’ docuseries premiere: How to watch for free todayJune 11, 2025 | cleveland.comCNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseRussell Rebalance: 3 Stocks Ready to Move HigherBy Chris Markoch | June 20, 2025View Russell Rebalance: 3 Stocks Ready to Move HigherAKRX, SPRO, GALT, TLC, and PHAS Company DescriptionsAkorn NASDAQ:AKRXAkorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.Galectin Therapeutics NASDAQ:GALT$2.09 -0.06 (-2.79%) Closing price 04:00 PM EasternExtended Trading$2.08 -0.01 (-0.48%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.PhaseBio Pharmaceuticals NASDAQ:PHASPhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.Spero Therapeutics NASDAQ:SPRO$2.94 +0.04 (+1.38%) Closing price 04:00 PM EasternExtended Trading$2.95 +0.01 (+0.34%) As of 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Taiwan Liposome NASDAQ:TLCTaiwan Liposome Co., Ltd. engages in the research and development of lipid-based formulation drugs. Its products are used for pain management, eye disease treatment, and cancer treatment. The company was founded by Kee Lung Hong on November 10, 1997 and is headquartered in Taipei, Taiwan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.